Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8598)	2/3/1999 1:24:00 PM
From: Cacaito	Respond to of 17367

Chlamydiae are the implicated bugs, (not bacteria, not virus, obligated intracellular organisms). They respond to some antibiotics like tetracyclines,quinolones (Cipro), and macrolides (erythromycin,Zitromax). Chlamydiae has been found on the atherosclesrosis plaques, and now they showed an association between use of these antibiotics and less heart disease. It is another piece in the causation role of Chlamydiae. Xoma has a patent about a Bpi peptide and is action against Chlamydiae. Some role in the future? maybe. But this antibiotics are very inexpensive, Bpi will have to do something beyond their abilities. Chlamydiae comes in two main varieties: trachomatis is the cause of a gonorrhae like sexually transmitted disease and much more common and prevalent in the USA than gonorrhae. About 2 million new cases a year, if I am remembering well. A clinical variant causes blindness in the Sahara desert (mainly in Egypt). Psitacci comes from birds and is much less common it usually affects the lungs. The trachomatis is the mainly implicated one.